Malignant neoplasm of breast, HER2-positive

PheWeb

C3_BREAST_HER2PLUS

No definition available.

Endpoint definition

↥

FinnGen phenotype data

individuals

Apply sex-specific rule

Sex only females

Check conditions

RX_HER2PLUS

Filter registries

Cause of death: ICD-10 C50

Cause of death: ICD-9 174

Cause of death: ICD-8 174

Cancer registry: Topography ICD-O-3 C50

Check pre-conditions, main-only, mode, ICD version

Look only at ICD versions C.O.D: 10, 8, 9

Check minimum number of events None

Include endpoints None

C3_BREAST_HER2PLUS

Extra metadata

Level in the ICD hierarchy 2

First used in FinnGen datafreeze DF5

Similar endpoints

↥

List of similar endpoints to Malignant neoplasm of breast, HER2-positive based on the number of shared cases.

Broader endpoints:

None

Narrower endpoints:

None

Show all endpoint correlations

Summary Statistics

↥

Key figures

All

Female

Male

Number of individuals

Unadjusted prevalence (%)

Mean age at first event (years)

?

Follow-up

Amount of time to look for the endpoint since entering the study. This is either either 1, 5, 15 years or the full study time from 1998 to 2019.

Absolute risk

Estimates the probability of dying from the current endpoint. Check the Documentation page for Mortality: absolute risk to get more details.

Hazard Ratio (HR) and 95% Confidence Interval (CI)

Measures how much the risk of dying increases (HR > 1) or decreases (HR < 1).

Number of individuals (N)

Number of individuals having the current endpoint and died during the follow-up time.
Mortality

Follow-up	Absolute risk	HR [95% CI]	p	N
1998–2019	-	-	-	-
15 years	-	-	-	-
5 years	-	-	-	-
1 year	-	-	-	-

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: C3_BREAST_HER2PLUS – Malignant neoplasm of breast, HER2-positive
GWS hits:

Survival analyses between endpoints

↥

Plot

before Malignant neoplasm of breast, HER2-positive
after Malignant neoplasm of breast, HER2-positive

Loading survival analyses plot

Table

Loading survival analyses table

Drugs most likely to be purchased after Malignant neoplasm of breast, HER2-positive

↥